Some people just never learn Matilda, or perhaps simply refuse to. InMed is going to dilute the heII out of this stock in the next quarter. Mark my words. Their terms will be terrible given the current SP and what they need to fund on the biosynthesis and EB programs this year.
And "undervalued" he says. Based on what? A rare skin disease trial and a biosynthesis program they can't commercialize. They may actually be overvalued at these levels.
News 
Market Data 
Discover 
